Document Detail


MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors.
MedLine Citation:
PMID:  15180527     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The Ras-Raf-MEK-ERK intracellular signaling cascade can be activated in response to a variety of extracellular stimuli. Growth factor binding to extracellular receptors results in activation of Ras, which in turn interacts with and activates Raf, leading to the phosphorylation of the dual specificity kinase MEK (MAP kinase kinase) on two distinct serine residues. MEK possesses a number of unique biochemical and biological features that make it an attractive target from an anticancer drug development perspective. The identification and subsequent testing of highly selective small molecule inhibitors of MEK have served to re-enforce the long held belief that the MEK/ERK module plays a critical role in controlling a number of cellular events that are critical to tumor cell growth and survival. We have witnessed advancement of the first MEK-targeted clinical drug candidate into clinical trials with the entry of CI-1040. The evaluation of sufficiently potent and selective MEK inhibitors in well-designed clinical trials is critical for ultimate validation of MEK as a molecular-based anticancer drug target.
Authors:
Judith S Sebolt-Leopold
Related Documents :
17205287 - Towards a new age in the treatment of multiple myeloma.
18606717 - Identification and characterization of nvp-bez235, a new orally available dual phosphat...
20197647 - Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigr...
15606337 - Targeting protein kinases in cancer therapy: a success?
25092827 - Reduction of nitric oxide level leads to spontaneous resumption of meiosis in diplotene...
9710127 - Fluid shear stress stimulates phosphorylation of akt in human endothelial cells: involv...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current pharmaceutical design     Volume:  10     ISSN:  1381-6128     ISO Abbreviation:  Curr. Pharm. Des.     Publication Date:  2004  
Date Detail:
Created Date:  2004-06-07     Completed Date:  2004-07-20     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9602487     Medline TA:  Curr Pharm Des     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1907-14     Citation Subset:  IM    
Affiliation:
Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48103, USA. judith.leopold@pfizer.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Drug Delivery Systems / methods*
Enzyme Inhibitors / pharmacology*
Humans
MAP Kinase Kinase Kinases / antagonists & inhibitors*,  metabolism
MAP Kinase Signaling System / drug effects*,  physiology
Neoplasms / drug therapy*,  enzymology
ras Proteins / antagonists & inhibitors,  metabolism
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; EC 2.7.11.25/MAP Kinase Kinase Kinases; EC 3.6.5.2/ras Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Targeting MAPK signalling: Prometheus' fire or Pandora's box?
Next Document:  Phosphoinositide 3-kinases as targets for therapeutic intervention.